Welcome to our dedicated page for BlackRock Health Sciences SEC filings (Ticker: BME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Blackrock Health Sciences Trust (BME) on Stock Titan is designed to centralize access to the trust’s regulatory disclosures when they are available from the U.S. Securities and Exchange Commission. Although no specific filings are listed in the provided data, a fund of this type typically uses SEC reports and registration documents to describe its investment objective, policies, and risks.
According to available information, Blackrock Health Sciences Trust seeks total return through current income, current gains, and long-term capital appreciation by investing 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and in equity derivatives. Regulatory filings are the primary source for these kinds of structural details, outlining how the trust is intended to operate and what constraints guide its portfolio.
On Stock Titan, users can review BME-related filings as they appear on EDGAR and use AI-powered tools to help interpret lengthy documents. These tools are intended to highlight key points, such as the fund’s investment objective, its 80% investment policy, and disclosures about the use of equity derivatives, without replacing the need to read official documents.
In addition to core registration and periodic reports, investors may also look for any filings that discuss changes to investment policies, risk disclosures, or other material updates affecting Blackrock Health Sciences Trust. The filings page brings these materials together and provides AI-generated summaries to make it easier to understand the regulatory information that defines the BME stock.
BME filed an N-CEN annual report that discloses operational information for its registered investment company, including securities lending activity, brokerage commissions and principal transaction volumes.
The report shows a monthly average value of portfolio securities on loan of $857,512.27 and securities lending net income of $15,085. Aggregate brokerage commissions paid during the reporting period were $339,015.19. Principal transaction records include a largest reported counterparty total value of $375,407,698.01.
BlackRock Health Sciences Trust (BME) filed its Form N-CSR for the fiscal year ended 12/31/2025, attaching the certified shareholder report and supplemental information covering distributions, portfolio summaries and strategy disclosures for BME and related BlackRock closed-end funds.
Key disclosures include a total per‑share cumulative distribution for BME of $3.145200 for the fiscal period (reported as 91% long‑term capital gains, 5% return of capital, 4% net income), fixed monthly distributions of $0.262100 per share, and a Board decision effective November 10, 2025 to remove the options writing strategy as a principal investment strategy.
BlackRock Health Sciences Trust portfolio manager Liu Xiang reported compensation-related transactions involving phantom shares and common stock. On January 30, 2026, Liu received 372.9639 phantom shares, each economically equivalent to one common share and payable in cash upon vesting. The filing also shows the exercise of previously granted phantom shares into 389.1035 common shares, followed by the disposition of those 389.1035 common shares at $41.87 per share, leaving no directly held common stock after the sale. Phantom share awards from 2023, 2024, 2025 and 2026 all vest in equal installments over three years.
BlackRock Health Sciences Trust portfolio manager Erin H. Xie reported a combination of phantom share awards and a stock sale. On January 30, 2026, 11,449.5087 shares of common stock were acquired through the exercise of derivative awards and then sold at $41.87 per share, leaving no directly held common stock.
Xie also received 6,379.1521 phantom shares, which are cash-settled units economically equivalent to common stock and vest in three annual installments, as described in prior and current phantom share grant footnotes.